Clinical Trial Update: Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas [Phase 1]

View source ↗

Summary

The Phase 1 study of AXT-1003 in adults with relapsed or refractory Non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• AXT-1003

Snippet

Sponsor: Axter Therapeutics (Beijing) Co., Ltd | Conditions: Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 1 | Status: TERMINATED